NOVANTA INC Q3 FY2026 earnings call

• Strategic Direction: Novanta is executing a deliberate strategy to become 'more medical, more recurring, and less cyclical.' Medical end markets now represent 53% of revenue, approaching 60% on a full-year basis.
• Key Competencies: Growth is driven by three proprietary platforms: Precision Motion/Robotics (servo drives, sensors), Precision Fluid/Flow Management (surgical insufflators, consumables), and Laser Beam Steering (ophthalmology, life sciences, semiconductors). Embedded software powers ~25% of revenue and 75% of new product launches.
• River Point Medical Integration: The acquisition was closed in July and is performing in line with expectations. It has expanded Novanta's addressable market in minimally invasive surgery consumables, which now represent ~25% of total revenue. Integration is progressing well with no significant issues.
• Innovation Pipeline: New product revenue grew 23% in Q3. Vitality index (new product sales as % of total) is ~27% year-to-date. Strong momentum in air bearing spindles (sold out for two years) and new servo drive families for humanoids and surgical robotics.
• Manufacturing Optimization: Novanta is consolidating factories to reduce complexity and cost, aiming for 18 facilities by Q1 2027 (down from 21). Regional manufacturing centers are being established to mitigate tariffs and logistics exposure. SAP MRP implementation is underway without disruption at lighthouse centers.
• Supply Chain: Despite tight supply for rare materials and electronic components, Novanta shielded customers by building safety stock earlier in the year.

The company operates through two primary reportable segments. The Medical Solutions segment generated $172 million in revenue (approximate calculation based on total $305M and industrial share), representing a 30% reported growth and ~3% organic growth, with River Point Medical contributing approximately $33 million. This segment accounts for roughly 53% of total revenue. The Automation Enabling Technologies segment generated $133 million in revenue, representing a 16% year-over-year growth. Within this segment, the Robotics & Automation business grew 17% and Precision Manufacturing grew 14%. Together, these segments comprise the remaining 47% of revenue.

• Q4 2026 Revenue: Expected between $306 million and $312 million, representing 18-21% year-over-year reported growth and 5-7% organic growth. Includes ~$35 million from River Point Medical.
• Q4 2026 Adjusted EBITDA: Expected between $76 million and $79 million, representing 25-30% year-over-year growth and ~25% margin (approx. 150 bps higher than prior year).
• Q4 2026 Adjusted EPS: Expected between $0.91 and $0.96.
• Full Year 2026 Revenue: Raised guidance to approximately $1,135 million - $1,140 million, representing ~16% reported growth and ~7% organic growth.
• Full Year 2026 Adjusted EBITDA: Expected between $274 million and $277 million, representing 24-25% year-over-year growth.
• Full Year 2026 Adjusted EPS: Expected between $3.66 and $3.71.
• Full Year 2026 Gross Margin: Expected to be approximately 46.5%, reflecting temporary headwinds from redundant factory costs at Stockport.
• Full Year 2026 Operating Cash Flow: Expected to generate approximately $200 million, a record for the company.
• 2027 Outlook: Management expects >15% reported revenue growth and >20% adjusted EBITDA growth, though specific numbers will be provided at year-end results.

• Stockport Facility Headwind: A major end-user found an issue requiring correction, leading to a production slowdown and shipment delay at the UK Stockport facility for the remainder of the year. This has created a 'perfect storm' of reduced revenue and redundant factory overhead costs, impacting Q4 gross margins by approximately 200 basis points.
• Supply Chain Constraints: Tight supply of rarer materials and electronic components across the industry poses a risk, though mitigated by early inventory buildup.
• Macroeconomic and Geopolitical Conditions: Shifty macroeconomic conditions and geopolitical tensions continue to impact the operating environment.
• Integration Risks: While River Point Medical is integrating well, any failure to realize synergies or capture expected growth could impact performance.

Q: Lee Jagoda asked for details on the Stockport facility issue, the magnitude of the gross margin headwind in Q3/Q4, and confidence that it won't leak into 2027.

A: CEO Matthijs Glastra explained that a major end-user identified an issue during sophisticated testing, causing a temporary shipment halt while corrections are made. Shipments are expected to resume in Q1 2027. CFO Robert Buckley added that a 'perfect storm' of redundant factory costs (due to site moves) and halted revenue caused a ~200 bps margin impact in Q4. He confirmed this is temporary, with margins rebounding to ~48% by Q2 2027 as redundant costs scale down and shipments resume.

Q: Lee Jagoda inquired about the capacity ramp for the air bearing spindles business, specifically if doubling capacity would fill by Q2 2027 or later, and the impact on gross margins.

A: CFO Robert Buckley clarified that the facility expansion doubles capacity, with a linear ramp expecting to fully fill that capacity by 2028. Shipping increases significantly in Q2 2027. Regarding margins, he noted that while there are temporary redundant costs during expansion, the spindles business has a better gross margin profile than the company average, so it does not negatively impact overall company margins once operational.

Q: Brian Drab asked about operating expense dynamics, specifically SG&A trends in Q4 given the River Point integration, and whether fewer selling days in Q4 would impact organic growth.

A: CFO Robert Buckley explained that Q2 SG&A was elevated due to bonus trued-ups from strong performance, which did not repeat in Q3. Q4 SG&A is expected to be slightly higher than Q3 but stable. CEO Matthijs Glastra addressed the calendar effect, stating that while there may be modest impacts from fewer selling days, the primary drivers are the temporary Stockport production hold and precision medicine lapping effects, which should accelerate in Q2 2027.